Glimepiride is a third generation sulfonylurea compound, which increases the release of insulin from pancreatic beta cells. In addition, Glimepiride increases the activity of intracellular insulin receptors. Studies conducted on adipocytes and skeletal muscle suggest that Glimepiride induces the PI3 kinase (PI3K) and Akt pathway, along with insulin receptor substrate-1/2 and endothelial nitric oxide synthase. Glimepiride also increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway. Furthermore, Glimepiride enhances intrinsic peroxisome proliferator-activated receptor γ activity. Glimepiride also increases protein expression of glucose transports 1 and 4, and is a potent KIR channel blocker.
API's & Drug Standards
|Appearance||crystalline powder form|
Send us your enquiry for Glimepiride. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Glimepiride email us and we will include your contribution on the website.